October 10, 2019
MGB Biopharma sees promising results from phase IIa clinical trial for potent oral bactericidal antibiotic targeting CDAD
MGB Biopharma has announced promising phase IIa clinical trial update for oral formulation MGB-BP-3, a potent oral bactericidal antibiotic targeting Clostridium Difficile-Associated Diarrhoea (CDAD), with – as it said in a press release – a completely novel mode of action.